Werewolf Therapeutics Inc (HOWL) News

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug...

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

– Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity...

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”...

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”...

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or...

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

– Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical...

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of...

Form 8-K - Current report

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

-  WTX-124 was shown to be clinically active and generally well-tolerated in patients who were...